Merck & Co., Inc. Furnishes Second-Quarter 2026 Financial Results
Summary
Merck & Co., Inc. furnished its second-quarter 2026 financial results on August 4, 2026, via Exhibit 99.1. The company reported total worldwide sales of $16.6 billion, reflecting 5% growth. GAAP loss per share was $0.54, and Non-GAAP loss per share was $0.13, both including a $2.31 per share charge for the acquisition of Terns. • KEYTRUDA/KEYTRUDA QLEX sales reached $8.4 billion (5% growth). • WINREVAIR sales grew 75% to $588 million. • Received U.S. FDA Approval for LIPFENDRA. • Announced positive data from TroFuse-005 Trial.
Why It Matters
Investors should note the reported GAAP and Non-GAAP losses per share, which include a significant $2.31 per share charge related to the acquisition of Terns, as detailed in Exhibit 99.1. This charge materially impacted profitability for the quarter, alongside strong sales growth in key product areas and pipeline advancements.
These filing summaries are free and always will be. If this helped you spot material events, consider supporting us.
Want to see how MRK traded around this filing?
Check real-time charts and technical analysis on TradingView to see market reaction to this event.
View MRK Charts on TradingViewAffiliate link
Is this filing part of a pattern?
One disclosure is noise. Get a structured briefing covering 12 months of SEC filings, disclosure signals, and what to watch next.
Key Quote
“by Merck & Co., Inc. on August 4, 2026, regarding earnings for the second quarter of 2026, attached as Exhibit 99.1.”
— From Item 2.02
Filing Details
Reported Items
Additional Information
- CIK Number
- 0000310158
- Filing Date
- Tuesday, August 4, 2026
- Filing Time
- 12:00 AM UTC
- Form Type
- 8-K
- Materiality Level
- high
- Sentiment
- positive